Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New treatment for fibromyalgia

09.09.2004


Study demonstrates effectiveness of the antidepressant duloxetine for improving symptoms and relieving pain



Fibromyalgia is a chronic, incapacitating musculoskeletal disorder. Nearly six times more common in women than in men, fibromyalgia is marked by widespread body pain and muscle tenderness, often accompanied by headaches, sleep disturbances, and fatigue. While its cause remains a mystery, fibromyalgia has been linked to abnormalities in the brain’s neurotransmitters, serotonin and norepinephrine--chemicals key to mood and widely recognized for their role in depression. Not all patients with fibromyalgia, however, have depression or respond to antidepressants. Treatment studies of the other types of antidepressant drugs, including selective serotonin uptake inhibitors and tricyclic agents, have had mixed results.

A new and different antidepressant, duloxetine, works by inhibiting the reuptake of both serotonin and norepinephrine. In a recent clinical trial conducted for the treatment of fibromyalgia--one of the largest ever--duloxetine was shown to reduce pain and improve a range of disease symptoms, significantly and safely. The results, published in the September 2004 issue of Arthritis & Rheumatism, offer the promise of relief for women with fibromyalgia.


"Our results suggest that duloxetine improves pain and tenderness, the hallmark characteristics of fibromyalgia," states Lesley M. Arnold, M.D., who coordinated the research at 18 centers, including the University of Cincinnati College of Medicine, Indiana University Medical School, and Harvard Medical School. "The effect of duloxetine on the reduction of pain," Dr. Arnold further notes, "appears to be independent of its effect on mood."

To test duloxetine’s effectiveness on the range of symptoms, researchers recruited 207 patients, all meeting the American College of Rheumatology criteria for fibromyalgia. Like the majority of those with this disease, the majority of the participants--89 percent--were women. 87 percent of the subjects were Caucasian and the mean age was 49. Just over a third of the patients--38 percent--had been diagnosed with depression. On a random basis, the patients were prescribed one of two treatments for a course of 12 weeks. About half, 104 individuals, received 60 milligrams of duloxetine twice a day. The remaining 103 patients were given a placebo. Both groups were evaluated and scored, using the Fibromyalgia Impact Questionnaire and other standard measures, for improvements in their condition.

In various measures of disease--from pervasive pain to tiredness to tenderness--the female fibromyalgia patients treated with duloxetine improved significantly over those treated with a placebo. One of the most dramatic changes was in the reduction of the number of tender points--places on the body where it hurts to touch--and the increase of pressure pain threshold. Women with or without depression receiving duloxetine benefited emotionally and physically, reporting improvements in general mood, ability to function, and overall enjoyment of life.

For the study’s 23 men, however, duloxetine did little to change their condition. Although researchers reported some evidence of improvement in tender point measures among duloxetine-treated men over their placebo-treated counterparts, it was not statistically significant. "The reasons for the sex differences in response are unclear," Dr. Arnold observes. "Because the male subgroup was small, reflecting the much higher prevalence of fibromyalgia in women, the results of the study may not be generalizable to all men with fibromyalgia. There may also be sex differences in fibromyalgia that affect treatment response."

As Dr. Arnold notes, further research is needed on larger samples of not only men but also other groups with fibromyalgia to evaluate duloxetine’s effectiveness.

Amy Molnar | EurekAlert!
Further information:
http://www.wiley.com

More articles from Health and Medicine:

nachricht Satellites, airport visibility readings shed light on troops' exposure to air pollution
09.12.2016 | Veterans Affairs Research Communications

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>